Strong partners ensure efficient market access
Who is Novaliq partnering with?
- Novaliq has an European Partnership Agreement with Ursapharm, one of the leading EU ophthalmic players. In October 2015, NovaTears® entered the EU market under Ursapharm’s brand name EvoTears®. Since then, EvoTears® has been successfully launched in 16 EU countries.
- Novaliq has a strategic Licencing Partnership Agreement with AFT Pharmaceuticals Ltd (AFT), a New Zealand-based pharmaceutical company listed in ASX and NZX, for the commercialization of NovaTears® in Australia and New Zealand.
- In April 2019, Novaliq has founded Betaliq Inc., Tampa USA in collaboration with BLP Management Group, LLC. Betaliq develops ophthalmic beta-blockers using Novaliq’s proprietary EyeSol® water-free technology.
- Novaliq is working with leading academic and industry partners including CROs, CMOs offering product development expertise and execution capabilities through pre-clinical IND, clinical development and regulatory in USA, Europe, China and Japan.
Do you want to partner with us?
Novaliq collaborates with leading scientific partners
Prof. Dr. med. Claus Cursiefen and Prof. Dr. med. Philipp Steven in the field of ophthalmic drug delivery for the anterior segment of the eye with special focus on dry eye disease.
Prof. Heping Xu, MD, PhD, in the field of retina diseases.
Dr. Ilva Rupenthal in the field of drug delivery technologies and ocular therapeutics.
Prof. Dr. med. Johannes Wohlrab in the field of penetration and dermatology.
Prof. Dr. Wolfgang Frieß in the field of protein formulation.
Prof. Gordon Tiddy and Dr. Robin Curtis in the field of basic research in formulation sciences.